| Article
Pharmacogenomics for clinical use: digital and validated
Save the date: Learn more about upcoming congresses, where you can meet bio.logis and talk to our team ...
Save the date: Learn more about upcoming congresses, where you can meet bio.logis and talk to our team ...
Read full article on medinside, published Oct 20th.
Medicines do not have the same effect on all patients. Because many factors affect drug response, physicians must select a drug that is appropriate for each individual and carefully adjust the dose. What many do not know and therefore often not considered in drug therapy: variants of DNA can lead to unwanted or insufficient drug effects (ADR). Get the whole story ....
The American AMP is responding with a position paper to the FDA-evoked discussions around PGx with clear recommendations on gene drug targets, laboratory and delivery of information for the POC.
Article on genomeweb
Association for Molecular Pathology Position Statement
The FDA's attention and UHC coverage indicate that PGx testing is finally coming to the standard care - in the US ...
Read free article on genomeweb.
by Daniela Steinberger
Genetisch bedingte Varianten von Proteinen des Medikamentenstoffwechsels können zu unerwünschten oder unzureichenden Arzneimittelwirkungen (UAW) führen.
Patient Empowerment/Förderung von E-Health Literacy/Shared Decision Making/digitale Patientenakten und Datenhoheit
Hier geht es zum vollständigen Artikel von Heike E. Krüger-Brand im Deutschen Ärzteblatt (Dtsch Arztebl 2019; 116(10): A-468 / B-382 / C-378).
Our CEO Prof. Daniela Steinberger will speak about the still to overcome challenges of implementing pharmacogenomics expertise in a clinical setting. She will show and and is happy to discuss the use of innovative digital solutions for genetic labs and hospitals to support the way towards personalised medicine and a better treatment of patients.
The talk will be held at the DELAB, Mainz, March 9th, 11:30 am.
For more information please contact us: info@biologis.com.
A recent article at GenomeWeb describes the joint efforts of bio.logis, the Medical University Vienna and the Robert-Bosch-Krankenhaus in Stuttgart, Germany to make pharmacogenetic analysis results available to patients through a unique drug safety card system.
The company bio.logis GIM GmbH has moved into a new and larger facilities on Olof-Palme-Strasse 15 in Frankfurt am Main on 01.08.2018 - only a few minutes away from the previous location on Campus Riedberg. With its new business premises, the international company founded in 2013 has created the conditions for the planned growth in the coming years.